ADMA Biologics Inc (NASDAQ:ADMA) Receives $28.00 Consensus Price Target from Analysts

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been assigned a consensus recommendation of “Buy” from the five ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $28.00.

A number of equities research analysts recently weighed in on the company. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Mizuho dropped their price objective on ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a research report on Monday.

Insider Activity

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms purchased 7,000 shares of the stock in a transaction on Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the acquisition, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. 3.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Westfield Capital Management Co. LP acquired a new position in ADMA Biologics in the third quarter valued at approximately $74,866,000. Janus Henderson Group PLC lifted its holdings in ADMA Biologics by 3,906.1% in the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock valued at $71,820,000 after acquiring an additional 3,838,158 shares during the period. Capital Research Global Investors lifted its holdings in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the period. Caligan Partners LP acquired a new position in ADMA Biologics in the third quarter valued at approximately $38,653,000. Finally, UBS Group AG lifted its holdings in ADMA Biologics by 129.9% in the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after acquiring an additional 2,581,670 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $10.65 on Monday. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $25.67. The stock’s 50-day moving average is $13.66 and its 200 day moving average is $15.86. The company has a market cap of $2.54 billion, a P/E ratio of 17.75 and a beta of 0.82. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. During the same quarter last year, the company earned $0.46 earnings per share. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. Research analysts predict that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.